Condition
Negative Symptoms With Primary Psychotic Disorder
Total Trials
5
Recruiting
3
Active
4
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04318977Not ApplicableActive Not RecruitingPrimary
rTMS Add on Value for Amelioration of Negative Symptoms of Schizophrenia
NCT04789915Phase 1Recruiting
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
NCT05252039Not ApplicableRecruiting
Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis
NCT04895488Phase 2Recruiting
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia
NCT04024371Completed
Validating Reward-related Biomarkers (RTOC)
Showing all 5 trials